DiaMedica Therapeutics Reports Strong Cash Position and Clinical Progress for DM199 Programs

summarizeSummary

DiaMedica Therapeutics reported full-year 2025 financial results, highlighting a strong cash position of $59.9 million, extending its operational runway through 2H 2027, alongside significant clinical progress in its DM199 preeclampsia and acute ischemic stroke programs.

check_boxKey Events

• Extended Cash Runway

  The company reported $59.9 million in cash and short-term investments as of December 31, 2025, up from $44.1 million in 2024. This capital is anticipated to fund operations through the second half of 2027, significantly de-risking the company's financial outlook. The increase was due to net proceeds from a July 2025 private placement and its at-the-market offering program.

• Preeclampsia Program Advancement

  DiaMedica received regulatory approval from Health Canada to initiate a Phase 2 DM199 study in early-onset preeclampsia. Enrollment is ongoing for the Part 1a expansion cohort of the Investigator-Sponsored Trial (IST), with completion expected in 1H 2026. The company also plans to initiate a DiaMedica-sponsored Phase 2 study later this year and expand it to the UK.

• Acute Ischemic Stroke Trial Progress

  Enrollment in the ReMEDy2 Phase 2/3 acute ischemic stroke trial of DM199 is approaching 70% of the required interim enrollment. The company reaffirms guidance for the completion of the interim analysis in the second half of 2026.

• Increased Operating Expenses

  Net loss for the year ended December 31, 2025, increased to $(32.8) million from $(24.4) million in 2024. Research and Development (R&D) expenses rose to $24.6 million from $19.1 million, primarily due to the continuation and global expansion of the ReMEDy2 clinical trial.

auto_awesomeAnalysis

This 8-K filing provides a comprehensive update on DiaMedica Therapeutics' financial position and clinical pipeline. The most significant takeaway is the robust cash and short-term investments of $59.9 million, which is projected to fund operations through the second half of 2027. This extended cash runway substantially de-risks the company's near-term financial outlook, a critical factor for clinical-stage biopharmaceutical companies. Additionally, the company reported positive advancements across its DM199 clinical programs, including regulatory approval in Canada for a Phase 2 preeclampsia study and significant enrollment progress in the ReMEDy2 acute ischemic stroke trial, with an interim analysis expected in 2H 2026. While the net loss and cash burn increased year-over-year, the strong cash position and consistent clinical execution are key positives for investors.